🚀 Investors Club invests in Resalis Therapeutics’ EUR 10 million round!

Special thanks to our champion Giulio Bonazzola, who has been instrumental in bringing this initiative to fruition. Guido’s active participation and commitment helped make this significant investment possible.

🤝 Special thanks to all the investors involved in the initiative: Sunstone Life Science Ventures with the participation of other investors including Claris Ventures.

Resalis Therapeutics, a company at the forefront of non-coding RNA (ncRNA) research, successfully closed the fundraising round. The funding will go towards the initiation and completion of the first Phase 1 clinical trial of RES-010, a promising candidate for the treatment of obesity.
RES-010, based on an innovative disease-modifying approach in obesity, aims to provide longer-lasting weight reduction. This investment represents a significant step for Resalis, allowing it to advance to the next phase of its core programme.